Update on the treatment and prevention of ischaemic stroke

Current Medical Research and Opinion

Volumn 19, Issue 5, 2003, Pages 438-441

  Alberts, Mark J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blockers; Cerebrovascular disease; Hypertension; Ischaemic stroke; Tissue plasminogen activators

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HEPARIN; HEPARINOID; STATIN; TISSUE PLASMINOGEN ACTIVATOR;

AGING; BLEEDING; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERTENSION; PUBLIC HEALTH; RISK FACTOR; STROKE; SURVIVAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CARDIOVASCULAR AGENTS; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RISK FACTORS; UNITED STATES;

EID: 0042233619     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001956     Document Type: Conference Paper

References (29)

1. National Health and Nutrition Survey III (1988-94). National Center for Health Statistics, Centers for Disease Control
2. Heart and stroke facts statistical supplement. Dallas: American Heart Association, 1998
3. Foulkes MR, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods and baseline characteristics. Stroke 1988;19:547-54
4. Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988-1997. Stroke 2001;32(10):2221-6
5. Alberts MJ. Hyperacute stroke therapy with tissue plasminogen activator. Am J Cardiol 1997;80(4C):29D-34D
6. Gubitz G, Counsell C, Sandercock P, et al. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systemic Reviews (Issue 4) 2002
7. Adams, Jr. HP, Bendixen BH, Leira E. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:122-5
8. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355(9211):1205-10
9. Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358(9283):702-10
10. Hommel M, for the FISS bis Investigators Group. Flaxiparine in Ischemic Stroke Study (FISS bis). Cerebrovasc Dis 1998;8(Suppl 4):52
11. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81
12. CAST (Chinese Acute Stroke Trial) Collaborative Group. Randomised, placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9
13. Adult Treatment Panel II National Cholesterol Education Program. Circulation 1994;89:1333-1435
14. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49(8):857-63
15. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326(6):381-6
16. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001;103(1):163-82
17. CAPRIE Steering Committee: a randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
18. Wong NN. Aggrenox: an aspirin and extended-release dipyridamole combination. Heart Dis 2001;3(5):340-6
19. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
20. National Stroke Association. Stroke/Brain Attack Briefing. Englewood, Colo: Postgraduate Institute for Medicine, 1999
21. Mohr JP, Thompson JLP, Lazar RM, et al. and the WARSS Study Group. N Engl J Med 2001;345:1444-5
22. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
23. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103(3):387-92
24. Waters DD, Schwartz GG, Olsson AG, et al. MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002;106(13):1690-5
25. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
26. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345(17):1243-9
27. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
28. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6150 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
29. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003